Nephrology visits and health care resource use before and after reporting estimated glomerular filtration rate

JAMA

Volumn 303, Issue 12, 2010, Pages 1151-1158

  Hemmelgarn, Brenda R ^a   Zhang, Jianguo ^a   Manns, Braden J ^a   James, Matthew T ^a   Quinn, Robert R ^a   Ravani, Pietro ^a   Klarenbach, Scott W ^c   Culleton, Bruce F ^a   Krause, Richard ^b   Thorlacius, Laurel ^d   Jain, Arsh K ^e   Tonelli, Marcello ^c  

^a UNIVERSITY OF CALGARY   (Canada)

^b CALGARY LABORATORY SERVICES   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

^d Diagnostic Services of Manitoba Inc   (Canada)

^e UNIVERSITY OF WESTERN ONTARIO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; COHORT ANALYSIS; COMORBIDITY; CONFIDENCE INTERVAL; CONSULTATION; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; EVALUATION; FEMALE; FOLLOW UP; GENERAL PRACTITIONER; GLOMERULUS FILTRATION RATE; HEALTH CARE UTILIZATION; HUMAN; HYPERTENSION; LABORATORY DIAGNOSIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PATIENT CARE; PRIORITY JOURNAL; PROTEINURIA; REGISTER; TIME SERIES ANALYSIS; AGE; AUTOMATION; CANADA; CLASSIFICATION; HEALTH CARE PLANNING; KIDNEY; KIDNEY DISEASE; LABORATORY; MIDDLE AGED; NEPHROLOGY; PATHOPHYSIOLOGY; PATIENT REFERRAL; SEX DIFFERENCE; STATISTICS; UTILIZATION REVIEW;

ADULT; AGE FACTORS; AGED; ALBERTA; AUTOMATION; COHORT STUDIES; FEMALE; GLOMERULAR FILTRATION RATE; HEALTH RESOURCES; HUMANS; KIDNEY; KIDNEY DISEASES; LABORATORIES; MALE; MIDDLE AGED; NEPHROLOGY; REFERRAL AND CONSULTATION; SEX FACTORS;

EID: 77949911220     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2010.303     Document Type: Article

References (47)

1. Meguid El Nahas A, Bello AK. Chronic kidney disease: the global challenge. Lancet. 2005;365(9456): 331-340.
2. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization. N Engl J Med. 2004;351(13):1296-1305.
3. Lewis EJ, Hunsicker LG, Clarke WR, et al; Collaborative Study Group. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345(12):851-860.
4. Wright JT Jr, Bakris G, Greene T, et al; African American Study of Kidney Disease and Hypertension Study Group. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002;288(19):2421-2431.
5. Jafar TH, Schmid CH, Landa M, et al. Angiotensinconverting enzyme inhibitors and progression of nondiabetic renal disease: a meta-analysis of patient-level data. Ann Intern Med. 2001;135(2): 73-87.
6. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial. Ann Intern Med. 2001;134(8):629-636.
7. Weiner DE, Tighiouart H, Amin MG, et al. Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies. J Am Soc Nephrol. 2004; 15(5):1307-1315.
8. Huisman RM. The deadly risk of late referral. Nephrol Dial Transplant. 2004;19(9):2175-2180.
9. Drey N, Roderick P, Mullee M, Rogerson M. A population-based study of the incidence and outcomes of diagnosed chronic kidney disease. Am J Kidney Dis. 2003;42(4):677-684.
10. National Kidney Disease Education Program. Laboratory professionals. 2004. http://www.nkdep.nih .gov/labprofessionals/index.htm. Accessed October 2009.
11. Levey AS, Coresh J, Balk E, et al; National Kidney Foundation. National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med. 2003; 139(2):137-147.
12. Akbari A, Swedko PJ, Clark HD, et al. Detection of chronic kidney disease with laboratory reporting of estimated glomerular filtration rate and an educational program. Arch Intern Med. 2004;164(16): 1788-1792.
13. Clase CM, Garg AX, Kiberd BA. Classifying kidney problems: can we avoid framing risks as diseases? BMJ. 2004;329(7471):912-915.
14. Glassock RJ, Winearls C. Screening for CKD with eGFR: doubts and dangers. Clin J Am Soc Nephrol. 2008;3(5):1563-1568.
15. Miller WG. Reporting estimated GFR: a laboratory perspective. Am J Kidney Dis. 2008;52(4): 645-648.
16. Hemmelgarn BR, Clement F, Manns BJ, et al. Overview of the Alberta Kidney Disease Network. BMC Nephrol. 2009;10:30.
17. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D; Modification of Diet in Renal Disease Study Group. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation: Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130 (6):461-470.
18. Levey AS, Coresh J, Greene T, et al; Chronic Kidney Disease Epidemiology Collaboration. Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem. 2007; 53(4):766-772.
19. Statistics Canada. Ethnocultural portrait of Canada highlight tables, 2006 Census. http://www12.statcan.ca/english/census06/data/highlights/ethnic/ index.cfm?Lang=E. Accessed June 15, 2009.
20. Manns BJ, Mortis GP, Taub KJ, McLaughlin K, Donaldson C, Ghali WA. The Southern Alberta Renal Program database: a prototype for patient management and research initiatives. Clin Invest Med. 2001; 24(4):164-170.
21. Hux JE, Ivis F, Flintoft V, Bica A. Diabetes in Ontario: determination of prevalence and incidence using a validated administrative data algorithm. Diabetes Care. 2002;25(3):512-516.
22. Quan H, Khan N, Hemmelgarn BR, et al; Hypertension Outcome and Surveillance Team of the Canadian Hypertension Education Programs. Validation of a case definition to define hypertension using administrative data. Hypertension. 2009;54(6): 1423-1428.
23. Quan H, Sundararajan V, Halfon P, et al. Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data. Med Care. 2005;43 (11):1130-1139.
24. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification.AmJ Kidney Dis. 2002; 39(2)(suppl 1):S1-S266.
25. Module 5: time series analysis. In: Pharmacoepidemiology: Behavioral and Cultural Themes. Newcastle, England: Center for Clinical Epidemiology and Biostatistics; 2001.
26. Cook TDCD. Quasi-experimentation: Design and Analysis Issues for Field Settings. Boston, MA: Houghton Mifflin Co; 1979.
27. Wagner AK, Soumerai SB, Zhang F, Ross-Degnan D. Segmented regression analysis of interrupted time series studies in medication use research. J Clin Pharm Ther. 2002;27(4):299-309.
28. Alberta Health and Wellness. Premium assistance program-premium subsidy. 2008. http://www.health.alberta.ca/AHCIP/premium-subsidy.html. Accessed May 2, 2008.
29. Swedko PJ, Clark HD, Paramsothy K, Akbari A. Serum creatinine is an inadequate screening test for renal failure in elderly patients. Arch Intern Med. 2003; 163(3):356-360.
30. Duncan L, Heathcote J, Djurdjev O, Levin A. Screening for renal disease using serum creatinine: who are we missing? Nephrol Dial Transplant. 2001; 16(5):1042-1046.
31. Tseng CL, Kern EF, Miller DR, et al. Survival benefit of nephrologic care in patients with diabetes mellitus and chronic kidney disease. Arch Intern Med. 2008; 168(1):55-62.
32. Hemmelgarn BR, Manns BJ, Zhang J, et al. Association between multidisciplinary care and survival for elderly patients with chronic kidney disease. J Am Soc Nephrol. 2007;18(3):993-999.
33. Jain AK, McLeod I, Huo C, et al. When laboratories report estimated glomerular filtration rates in addition to serum creatinines, nephrology consults increase. Kidney Int. 2009;76(3):318-323.
34. Aghaie-Jaladerany H, Cowell D, Geddes CC. The early impact of the United Kingdom Chronic Kidney Disease (CKD) guidelines on the number of new attendances at renal clinics. Scott Med J. 2007;52 (4):28-31.
35. Noble E, Johnson DW, Gray N, et al. The impact of automated eGFR reporting and education on nephrology service referrals. Nephrol Dial Transplant. 2008;23(12):3845-3850.
36. Wyatt C, Konduri V, Eng J, Rohatgi R. Reporting of estimated GFR in the primary care clinic.Am J Kidney Dis. 2007;49(5):634-641.
37. Brenner BM, Cooper ME, de Zeeuw D, et al; RENAAL Study Investigators. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001; 345(12):861-869.
38. O'Hare AM, Kaufman JS, Covinsky KE, Landefeld CS, McFarland LV, Larson EB. Current guidelines for using angiotensin-converting enzyme inhibitors and angiotensin II-receptor antagonists in chronic kidney disease: is the evidence base relevant to older adults? Ann Intern Med. 2009;150(10):717-724.
39. Bertoni AG, Bonds DE, Chen H, et al. Impact of a multifaceted intervention on cholesterol management in primary care practices: guideline adherence for heart health randomized trial. Arch Intern Med. 2009;169(7):678-686.
40. Ornstein S, Jenkins RG, Nietert PJ, et al. A multimethod quality improvement intervention to improve preventive cardiovascular care: a cluster randomized trial. Ann Intern Med. 2004;141(7): 523-532.
41. Davis D, Galbraith R; American College of Chest Physicians Health and Science Policy Committee. Continuing medical education effect on practice performance: effectiveness of continuing medical education: American College of Chest Physicians Evidence-Based Educational Guidelines. Chest. 2009;135(3)(suppl):42S-48S.
42. Rainey PM. Automatic reporting of estimated glomerular filtration rate-jumping the gun? Clin Chem. 2006;52(12):2184-2187.
43. Mathew TH; Australasian Creatinine Consensus Working Group. Chronic kidney disease and automatic reporting of estimated glomerular filtration rate: a position statement. Med J Aust. 2005;183(3): 138-141.
44. den Hartog JR, Reese PP, Cizman B, Feldman HI. The costs and benefits of automatic estimated glomerular filtration rate reporting. Clin JAmSoc Nephrol. 2009;4(2):419-427.
45. Bauer C, Melamed ML, Hostetter TH. Staging of chronic kidney disease: time for a course correction. J Am Soc Nephrol. 2008;19(5):844-846.
46. Glassock RJ. Estimated glomerular filtration rate: time for a performance review? Kidney Int. 2009; 75(10):1001-1003.
47. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med. 2004; 351(6):543-551.